March 23, 2021
Investigational AstraZeneca vaccine prevents COVID-19
Results from a large clinical trial in the United States and South America indicate that AstraZeneca’s COVID-19 vaccine, AZD1222, is…
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
March 22, 2021
AstraZeneca’s head of cancer research José Baselga dies at age of 61
AstraZeneca has confirmed that their Executive Vice President Oncology R&D, and member of Senior Executive Team, José Baselga has passed away.
March 22, 2021
Bavardian Nordic nets $31.2M deal with Public Health Agency of Canada
Bavarian Nordic got a $31.2million worth of Imvamune vaccines order from Public Health Agency of Canada (PHAC).
March 19, 2021
UK and EU regulatory agencies confirm COVID-19 Vaccine AstraZeneca is safe and effective
Today the Medicines and Healthcare products Regulatory Agency (MHRA) and European Medicines Agency (EMA) reaffirmed the benefits of COVID-19 Vaccine AstraZeneca continue to far outweigh the risks.
March 15, 2021
Sanofi, Regeneron post positive results in P3 testing of Libtayo (oncology) monotherapy
Sanofi and Regeneron posted positive results with an overall survival (OS) benefit from the Phase 3 trial investigating its PD-1 inhibitor Libtayo (cemiplimab) monotherapy compared to chemotherapy in patients previously treated with chemotherapy whose cervical cancer is recurrent or metastatic.
March 15, 2021
Roche buys genMak for $1.8 billion
Roche is buying GenMark at a price of US$ 24.05 per share in an all-cash transaction, the companies announced Monday agreement with a total transaction value of approximately US$ 1.8 billion.
March 14, 2021
AstraZeneca responds to another country halting use of its vaccine
Ireland has temporarily halted using AstraZeneca’s Covid-19 vaccine Sunday, which came after a report from Norway of patients developing blood clots post inoculation.
March 12, 2021
Roche’s study trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia misses goal
Roche said Thursday that the global phase III randomised, double-blind, multicentre study of Actemra®/RoActemra® (tocilizumab) plus Veklury® (remdesivir), versus placebo plus Veklury, did not meet its primary endpoint.
March 9, 2021
Shield Therapeutics’ Feraccru registered in Australia for anaemia
Shield Therapeutics said Tuesday that Australia’s Therapeutics Goods Administration has registered its lead product Feraccru in the Australian Register of Therapeutic Goods to treat iron deficiency with or without anaemia in adults.
March 9, 2021
Novartis’ Phase III CANOPY-2 trial misses goal
Novartis said Tuesday its Phase III CANOPY-2 trial did not meet primary endpoint of overall survival in patients with advanced or metastatic non-small cell lung cancer whose cancer progressed while on or after previous treatments.